$FBRX
Forte Biosciences, Inc.

2019 Q1 Form 10-K Financial Statement

#000156459019004933 Filed on February 27, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 2017 Q4
Revenue $9.000K $18.04M $10.00K
YoY Change 43890.24% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.450M $12.81M $2.400M
YoY Change 83.88% 49.65% 77.78%
% of Gross Profit
Research & Development $12.43M $51.08M $8.290M
YoY Change 19.15% 75.45% 25.04%
% of Gross Profit
Depreciation & Amortization $216.0K $625.0K $90.00K
YoY Change 127.37% 114.04% 28.57%
% of Gross Profit
Operating Expenses $16.88M $63.89M $10.70M
YoY Change 31.31% 69.61% 33.95%
Operating Profit -$16.87M -$45.85M
YoY Change 31.33% 21.86%
Interest Expense -$210.0K -$1.400M -$150.0K
YoY Change 600.0% 7.69% -67.39%
% of Operating Profit
Other Income/Expense, Net -$213.0K
YoY Change 526.47%
Pretax Income -$17.08M -$47.26M -$10.84M
YoY Change 32.61% 21.39% 28.59%
Income Tax $1.699M
% Of Pretax Income
Net Earnings -$1.185M -$48.96M -$10.84M
YoY Change -90.8% 25.75% 28.55%
Net Earnings / Revenue -13166.67% -271.43% -108370.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$11.09M -$36.54M -$8.150M
COMMON SHARES
Basic Shares Outstanding 23.02M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $80.12M $96.10M $88.73M
YoY Change 8.28% 8.34% 183.97%
Cash & Equivalents $31.00M $40.80M $35.93M
Short-Term Investments $49.13M $55.30M $52.79M
Other Short-Term Assets $1.600M $1.700M $1.900M
YoY Change -48.39% -10.53% 58.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $81.69M $97.70M $90.63M
YoY Change 5.95% 7.84% 179.19%
LONG-TERM ASSETS
Property, Plant & Equipment $3.813M $4.000M $1.217M
YoY Change 172.36% 233.33% 63.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $1.400M $227.0K
YoY Change 550.0% 600.0% -89.43%
Total Long-Term Assets $13.01M $5.400M $1.444M
YoY Change 713.19% 260.0% -50.03%
TOTAL ASSETS
Total Short-Term Assets $81.69M $97.70M $90.63M
Total Long-Term Assets $13.01M $5.400M $1.444M
Total Assets $94.70M $103.1M $92.07M
YoY Change 20.33% 11.94% 160.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.800M $3.400M $1.951M
YoY Change 55.56% 70.0% 17.11%
Accrued Expenses $11.20M $13.10M $8.120M
YoY Change 41.77% 61.73% 49.35%
Deferred Revenue $36.00K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.200M $0.00 $7.200M
YoY Change -69.44% -100.0% 0.0%
Total Short-Term Liabilities $16.20M $16.50M $17.33M
YoY Change -4.14% -4.62% 20.5%
LONG-TERM LIABILITIES
Long-Term Debt $24.10M $26.20M $3.625M
YoY Change 1105.0% 627.78% -64.6%
Other Long-Term Liabilities $9.600M $2.200M $0.00
YoY Change 4700.0% -100.0%
Total Long-Term Liabilities $33.70M $28.40M $3.625M
YoY Change 1431.82% 688.89% -64.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.20M $16.50M $17.33M
Total Long-Term Liabilities $33.70M $28.40M $3.625M
Total Liabilities $49.90M $44.90M $20.99M
YoY Change 161.79% 113.81% -25.97%
SHAREHOLDERS EQUITY
Retained Earnings -$233.0M -$166.9M
YoY Change 29.56% 30.41%
Common Stock $277.8M $238.0M
YoY Change 15.95% 6543.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.919M $58.10M $71.08M
YoY Change
Total Liabilities & Shareholders Equity $94.73M $103.1M $92.07M
YoY Change 20.31% 11.94% 160.45%

Cashflow Statement

Concept 2019 Q1 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$1.185M -$48.96M -$10.84M
YoY Change -90.8% 25.75% 28.55%
Depreciation, Depletion And Amortization $216.0K $625.0K $90.00K
YoY Change 127.37% 114.04% 28.57%
Cash From Operating Activities -$17.68M -$34.47M -$9.170M
YoY Change 39.14% 10.72% 18.32%
INVESTING ACTIVITIES
Capital Expenditures $133.0K $1.968M -$320.0K
YoY Change -39.55% 200.46% 3100.0%
Acquisitions
YoY Change
Other Investing Activities $6.230M -$2.220M -$28.08M
YoY Change -281.1% -91.79% -509.93%
Cash From Investing Activities $6.097M -$4.190M -$28.40M
YoY Change -266.54% -84.88% -515.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $248.0K $661.0K
YoY Change 755.17% 30.37%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.770M 43.54M -1.340M
YoY Change -199.94% -51.22% -157.51%
NET CHANGE
Cash From Operating Activities -17.68M -34.47M -9.170M
Cash From Investing Activities 6.097M -4.190M -28.40M
Cash From Financing Activities 1.770M 43.54M -1.340M
Net Change In Cash -9.815M 4.880M -38.91M
YoY Change -45.89% -83.96% -2840.14%
FREE CASH FLOW
Cash From Operating Activities -$17.68M -$34.47M -$9.170M
Capital Expenditures $133.0K $1.968M -$320.0K
Free Cash Flow -$17.82M -$36.44M -$8.850M
YoY Change 37.8% 14.63% 14.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215884000
CY2017 us-gaap Operating Expenses
OperatingExpenses
37669000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
274029000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8556000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-45853000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4521000
CY2018 us-gaap Operating Expenses
OperatingExpenses
63889000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-48955000
CY2016 us-gaap Operating Expenses
OperatingExpenses
31739000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12809000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6870000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
157000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
304000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
586000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4127000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2946000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-124417000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34469000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-38929000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-23000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29113000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27218000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-37628000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-31690000
CY2018 us-gaap Interest Income Other
InterestIncomeOther
1534000
CY2017 us-gaap Interest Income Other
InterestIncomeOther
595000
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
2937000
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23019097
CY2018Q2 dei Entity Public Float
EntityPublicFloat
186000000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40813000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35933000
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
55273000
CY2017Q4 us-gaap Marketable Securities
MarketableSecurities
52792000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1662000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1904000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
97748000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
90629000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3973000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1217000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1360000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
227000
CY2018Q4 us-gaap Assets
Assets
103081000
CY2017Q4 us-gaap Assets
Assets
92073000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24567000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
23003000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
655000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
525000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4190000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
36000
CY2017Q4 us-gaap Liabilities
Liabilities
20991000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3404000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1951000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13094000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8120000
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7200000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
36000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
36000
CY2017Q4 toca Deferred Grant Funding
DeferredGrantFunding
23000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16534000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17330000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26201000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3625000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2201000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23000151
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19882551
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23000151
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19882551
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18036000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41000
CY2016 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49000
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2017 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2016 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51080000
CY2016 us-gaap Interest Income Other
InterestIncomeOther
215000
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
1932000
CY2016 us-gaap Interest Expense Debt
InterestExpenseDebt
2052000
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-37000
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-50000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47256000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38928000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33477000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1699000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-33478000
CY2018 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
11000
CY2017 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-34000
CY2016 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
58000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48944000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38963000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33420000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.44
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.66
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.22
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20059541
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14607609
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2199964
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-92330000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
-92330000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1323000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
58000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
426000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4451000
CY2017 toca Conversion Of Preferred Stock To Common Stock Amount Converted
ConversionOfPreferredStockToCommonStockAmountConverted
131410000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
86948000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
11057000
CY2017 toca Preferred Stock Warrants Liabilities Converted Into Warrants To Purchase Share Of Common Stock
PreferredStockWarrantsLiabilitiesConvertedIntoWarrantsToPurchaseShareOfCommonStock
89000
CY2018 toca Deferred Equity Issuance Costs Incurred But Not Yet Paid
DeferredEquityIssuanceCostsIncurredButNotYetPaid
310000
CY2017 toca Deferred Equity Issuance Costs Incurred But Not Yet Paid
DeferredEquityIssuanceCostsIncurredButNotYetPaid
96000
CY2018 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
8631000
CY2018 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3000000
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7200000
CY2016 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
600000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
661000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
507000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10000
CY2018 toca Proceeds From Offering Of Common Net Of Stock Issuance Costs
ProceedsFromOfferingOfCommonNetOfStockIssuanceCosts
28200000
CY2017 toca Proceeds From Offering Of Common Net Of Stock Issuance Costs
ProceedsFromOfferingOfCommonNetOfStockIssuanceCosts
88618000
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7338000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-34000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
594000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27997000
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
479000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
6870000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
4451000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1323000
CY2018 us-gaap Depreciation
Depreciation
625000
CY2017 us-gaap Depreciation
Depreciation
292000
CY2016 us-gaap Depreciation
Depreciation
255000
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
1161000
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
590000
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
570000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
248000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
19000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
9000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
20000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
208000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
679000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1260000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1547000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-41000
CY2016 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-49000
CY2018 toca Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
958000
CY2018 toca Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-23000
CY2017 toca Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-11000
CY2016 toca Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-57000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31133000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29539000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
68524000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
43725000
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
48095000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
70746000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
70797000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1968000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
20000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27707000
CY2018 toca Proceeds From Issuance Of Notes Payable Net Of Issuance Costs
ProceedsFromIssuanceOfNotesPayableNetOfIssuanceCosts
26325000
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3374000
CY2016 toca Proceeds From Convertible Promissory Note Subscriptions
ProceedsFromConvertiblePromissoryNoteSubscriptions
140000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
16000
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
592000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43539000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
89263000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2332000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3544085
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2600008
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8086581
CY2017Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4880000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
30423000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2640000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5510000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8150000
CY2018 us-gaap Interest Paid
InterestPaid
1522000
CY2017 us-gaap Interest Paid
InterestPaid
1210000
CY2016 us-gaap Interest Paid
InterestPaid
1460000
CY2018 toca Allowance For Tenant Improvements Included In Deferred Rent
AllowanceForTenantImprovementsIncludedInDeferredRent
1243000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
178000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
111000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
28000
CY2018 toca Fair Value Of Common Stock Warrants Issued In Connection With Notes Payable
FairValueOfCommonStockWarrantsIssuedInConnectionWithNotesPayable
479000
CY2017 toca Convertible Preferred Stock Converted Into Shares Of Common Stock
ConvertiblePreferredStockConvertedIntoSharesOfCommonStock
131410000
CY2017 toca Convertible Promissory Notes Principal And Accrued Interest Converted Into Shares Of Common Stock
ConvertiblePromissoryNotesPrincipalAndAccruedInterestConvertedIntoSharesOfCommonStock
11057000
CY2017 toca Deferred Equity Issuance Cost Payment Reclassified Of Equity Effective Intial Public Offering
DeferredEquityIssuanceCostPaymentReclassifiedOfEquityEffectiveIntialPublicOffering
1574000
CY2016 toca Deferred Equity Issuance Costs Incurred But Not Yet Paid
DeferredEquityIssuanceCostsIncurredButNotYetPaid
226000
CY2018 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements are prepared in accordance with accounting principles generally accepted in the United States, which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements accompanying notes. Significant estimates in the Company&#8217;s financial statements relate to clinical trial accruals, the valuation of equity awards, and the development period used for license revenue recognition. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Off-Balance Sheet Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash equivalents and marketable securities. The Company&#8217;s investment policy includes guidelines for the quality of the related institutions and financial instruments, and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk.</p>
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018 us-gaap Initial Offering Period
InitialOfferingPeriod
April 19, 2017
CY2017Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
86900000
CY2018Q4 toca Working Capital
WorkingCapital
81200000
CY2018Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
96100000
CY2018 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2017 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2018 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
more than 50 percent
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
100000
CY2017 toca Warrant Liability
WarrantLiability
0
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
55296000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
52823000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
55273000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
52792000
CY2018 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
0
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7304000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.003
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3923000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3331000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2706000
CY2018Q4 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
4535000
CY2017Q4 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
2809000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2840000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2489000
CY2018Q4 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
3411000
CY2017Q4 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
1536000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
474000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
276000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
205000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
77000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1629000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
933000
CY2017Q2 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
11100000
CY2017Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1109176
CY2017Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
10.00
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6318000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2194000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1087000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
67000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
81000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
508000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
677000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
62000
CY2018 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
122648
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6870000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4451000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1323000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1698000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1699000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.061
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.057
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.056
CY2018 toca Effective Income Tax Rate Reconciliation Withholding Tax
EffectiveIncomeTaxRateReconciliationWithholdingTax
-0.036
CY2018 toca Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
-0.010
CY2017 toca Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
-0.045
CY2016 toca Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
-0.054
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.037
CY2018 toca Effective Income Tax Rate Reconciliation Net Operating Loss Carryovers Not Recognized
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryoversNotRecognized
-0.221
CY2017 toca Effective Income Tax Rate Reconciliation Net Operating Loss Carryovers Not Recognized
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryoversNotRecognized
-0.304
CY2016 toca Effective Income Tax Rate Reconciliation Net Operating Loss Carryovers Not Recognized
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryoversNotRecognized
-0.328
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.059
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.010
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.011
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.019
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.037
CY2017Q4 toca Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
52000
CY2018Q4 toca Deferred Tax Assets Deferred License Revenue
DeferredTaxAssetsDeferredLicenseRevenue
10000
CY2017Q4 toca Deferred Tax Assets Deferred License Revenue
DeferredTaxAssetsDeferredLicenseRevenue
15000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3432000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1459000
CY2018Q4 toca Deferred Tax Assets Tax Debt Discount
DeferredTaxAssetsTaxDebtDiscount
137000
CY2018Q4 toca Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
1778000
CY2017Q4 toca Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
808000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5357000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2334000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5107000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2334000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
250000
CY2018Q4 toca Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
250000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
250000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2600000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
400000
CY2018Q4 toca Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
CY2018 toca Period For Cumulative Change In Ownership
PeriodForCumulativeChangeInOwnership
P3Y
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42000000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
30400000
CY2018Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2018 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the IRC. Participating employees may defer up to the Internal Revenue Service annual contribution limit. The Company has elected to match 50% of an employee’s contributions up to 6% of the employees’ eligible salary beginning January 1, 2019. The Company has not made any contributions for the years ended December 31, 2018, 2017 and 2016.
CY2017 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0
CY2016 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1759000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1939000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2007000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2077000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2150000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5700000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
15632000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
12855000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
15336000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
16582000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
19116000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-12880000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-16089000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-383000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-19603000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
8564000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
8662000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
9747000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
10696000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-9073000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-9066000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-9953000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-10837000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.11
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55

Files In Submission

Name View Source Status
0001564590-19-004933-index-headers.html Edgar Link pending
0001564590-19-004933-index.html Edgar Link pending
0001564590-19-004933.txt Edgar Link pending
0001564590-19-004933-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gcixbjd5kiqi000001.jpg Edgar Link pending
gcixbjd5kiqi000002.jpg Edgar Link pending
gcixbjd5kiqi000003.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
toca-10k_20181231.htm Edgar Link pending
toca-20181231.xml Edgar Link completed
toca-20181231.xsd Edgar Link pending
toca-20181231_cal.xml Edgar Link unprocessable
toca-20181231_def.xml Edgar Link unprocessable
toca-20181231_lab.xml Edgar Link unprocessable
toca-20181231_pre.xml Edgar Link unprocessable
toca-ex103_574.htm Edgar Link pending
toca-ex231_12.htm Edgar Link pending
toca-ex311_8.htm Edgar Link pending
toca-ex312_6.htm Edgar Link pending
toca-ex321_14.htm Edgar Link pending